2020 Medical People Eat Melon Summary Report

Later, as the outbreak was gradually under control, everyone's life became more and more normal.
in the medical circles began to stage one after another "farce", stirring up the mood of the crowd.
"play people" hold their hearts, "outsiders" eat melons.
, turn around and look back, and we might as well look back at the "dramas" that made a "full of wind and rain" in the circle.
30, 2020, the anti-epidemic doctor Effen self-explosion of his retinal shedding after surgery in Eyre Ophthalmology sparked a heated online debate.
New Year's Day holiday is in the hot search list for a long time, "the first stock of private hospitals" Er ophthalmology, which encountered a huge crisis.
the evening of December 31st, Wuhan Eyre Ophthalmology issued a statement saying that Dr. Aifen's right eye was a highly nearstriopian consonatory cataract, and that Ms. Effin's right eye retina was not directly related to her cataract surgery.
4 January, the Eyre Ophthalmology Group released a verification report on the treatment of Effen.
report again indicated that ms. Iffin's right eye retina detachment was not directly related to her cataract surgery.
January 5, Wuhan Wuchang District Medical Adjustment Committee stepped in to mediate the dispute between Eyre Ophthalmology and Aifen.
the incident continues to fester and no settlement has yet been reached between the parties.
,2020, Watson Bio announced the transfer of a 32.60% stake in Shanghai Zerun for 1,141 million yuan.
the deal is completed, Shanghai Zerun will no longer be its controlling subsidiary.
announcement, which prompted a thing of investors, and questions about Watson's bio-selling continued to grow.
investment institutions believe that the market of similar enterprises Wantay Bio has a valuation of nearly 80 billion, Watson Bio this sale of Shanghai Zerun shares corresponding to the Shanghai Zerun valuation of only 3.5 billion yuan, in addition, Shanghai Zerun two-price HPV vaccine has been reported and is expected to be approved, the current transfer of 1.141 billion yuan of Shanghai Zerun shares is a veritable "sold" assets.
the following day, Watson Bio held an investor conference call for the equity transfer.
of institutional investors have raised the central issue of selling assets at a low price, and some have even said they will report it to the SFC.
the morning of December 7, Watson Bio announced that it had temporarily suspended its share transfer proposal to Shanghai Zerun.
's subsequent comments about Watson's biological "confessions" and "fear of being regulated" have been raucous.
same day, Watson Bio received a letter of concern from the Shenzhen Stock Exchange asking the company to verify the response to relevant market concerns.
On the evening of December 8th, Watson Bio issued a reply to the Shenzhen Stock Exchange's letter of concern, saying, "There is no correlation or other interest arrangement between the investors and the top ten shareholders of the listed company (as of September 30, 2020), and the directors of the listed company."
" Beast Hand TearIng Jun real creatures November 12, 2020, an article published from the media WeChat public number "Beast House" ("Jianghu is the world of humanity") brushed up the circle of friends of medical people.
In this article, the author mainly raised four questions about Junshi Biological: the research and development team's low education, too much moisture;
As things fermented, the SSE sent out an inquiry letter questioning the rate of adverse reactions to core products, the suspension of clinical trials of new crowns and antibodies, and the educational qualifications of the research and development team.
to see junshi Bio's clarification announcement on the Hong Kong Stock Exchange only addressed the rate of Terripri single anti-adverse reactions and the cooperation with Lilly, including the new crown drug JS016.
chose to avoid talking about the level of education and leadership of the research and development team.
Junshi Biological issued a reply to the inquiry letter announced that the "river and lake is the world of humanity" article reported that the contents of the comprehensive misre facts, and objective facts seriously inconsistent with and contrary.
the negative impact of this article, the real creatures on the "beast" to take legal means.
October 27, 2020, Furen Pharmaceuticals announced to the public that the company had received the Administrative Penalty Decision issued by the CSRC and the Market Ban Decision.
documents show that Furen Pharmaceuticals' performance has been false for years, and the company and related personnel have been fined a total of 5.9 million yuan.
, zhu Wenchen, the company's real controller, has been banned from the securities market for 10 years.
as of July 19, 2019, Furen Pharmaceuticals announced that it intended to pay its 2018 annual cash dividend on July 22, 2019, with a total cash dividend of approximately $62.7158 million, which could not be paid as planned due to the company's capital arrangements.
2019 quarterly report shows that the monetary capital of 1.816 billion yuan, but only in the past four months, but can not get 60 million yuan in dividends? This inevitably caused a storm, the Shanghai Stock Exchange also issued an inquiry letter.
July 24, 2019, Furen Pharmaceuticals announced that the Company's financial information shows that as of July 19, the Company and its subsidiaries had a total cash of 127 million yuan, most of which is still in a restricted state, the restricted amount of 123 million yuan, the unlimited amount of only 3.7787 million yuan.
previously released figures, nearly 1.7 billion yuan of funds are missing.
in fact, for the financial fraud of Furen Pharmaceuticals, as early as 2015 has been reported in real name, and lightning point trigger is inevitable.
this financial fraud, the damage to the reputation of the enterprise is perhaps the most critical.
on September 21, 2020, Kingsley's founder, Zhang Fangliang, announced that his company's offices in Nanjing and Zhenjiang had been inspected by China's customs and anti-smuggling authorities for alleged violations of Chinese law on imports and exports.
investigation, Zhang Fangliang, chairman, non-executive director and one of the controlling shareholders, is currently under surveillance and four other employees have been detained for questioning.
Two months after the fermentation continued, on November 22nd Kingsley Bio again announced that Zhang Fangliang, chairman of the company's board of directors, had been arrested for "suspected smuggling of goods prohibited by Chinese law on import and export" and that Zhang Fangliang or the employees involved had not been formally charged.
addition, the company said that Mr. Zhang had resigned as a non-executive director, chairman of the board of directors, member and chairman of the company's nomination committee, member and chairman of the company's sanctions risk control committee, and director of Legendary Biotech Limited.
company appointed Zhu Li to the board of directors of Legendary Biotechnology as a director of three categories.
At the same time, the Kingsley Biotech Board also announced that Zhu Li had been appointed as an Executive Director, Wang Xuehai had been appointed as an Independent Non-executive Director, Meng Jiange had been appointed Chairman of the Board of Directors and Wang Wei had been appointed Chairman of the Company's Sanctions Risk Control Committee.
zhang Fangliang get caught? Kingsley did not specify, but industry insiders speculated that Kingsley's involvement may have violated the National Office of Human Genetic Resource Collection on the exit of human genetic resources, the incident or human genetic violations of the exit.
on September 7, 2020, a whistleblower letter appeared on the wall of Linyi People's Hospital, directly named the secretary and president of the hospital, pointing out that doctors in the oncology and radiotherapy departments of the hospital received kickbacks.
letter mentioned that Linyi City People's Hospital Oncology Department used hydrochloric acid arotetini capsules, retail price of 3409 yuan / box, "the hospital oncologists, radiotherapy doctors, even take 400 rebates per box."
letter also said that from 2019 to date, Linyi City People's Hospital oncology department, radiotherapy department four doctors took bribes totalling between 100,000 yuan and 200,000 yuan.
and hydrochloric acid atrotini capsules, which are the drug of Zhengda Tianqing.
In addition, the whistleblower letter also "named" three other drugs that were being produced on a positive day's day involving rebates, namely, the magnesium glyphosate injection for the treatment of chronic viral hepatitis (Tianqing Gamma), the injection of Esomeprazole (Estrapin), and Biabenan (tiansin injection).
fact, this is not the first time it has been reported.
has been blacklisted by authorities for its involvement in a number of commercial bribery cases.
the company's sales executives were arrested and drugs were disqualified from online procurement and distribution.
a similar letter appeared on the wall of the First Hospital affiliated with Anhui Medical University on September 1st, not long after the letter was posted.
letter, some of the hospital's doctors and medical representatives in Zhengda Tianqing have an abnormal sales relationship, with gold sales.
is in the hospital with narcotic-related drugs, cancer drugs, etc. , for every box of drugs sold, to prescription doctors about 12% of the price of cash.
on September 10, 2020, an "open letter to every Gautam" from Mrs. Cai Dajian ( or Jin Huili) , chairman of the well-known medical investment agency Gottlieb, circulated on the Internet, and for a time the entire medical circle joined the melon-eating camp.
wrote in an open letter that her husband, Cai Dajian, had acted in violation of the company's interests in the "affair".
with the release of the open letter, Boya Bio, another publicly traded company that Gottja has invested in, is in crisis.
Cai Dajian by virtue of equity holdings and other ways to conceal his identity as Boya biological real controller, and behind the capital operation traces are gradually picked out.
2007, Cai Dajian Investments controlled Boya Bio.
starting in 2017, Boya Bio has been injecting long-term funds into Danxia Bio, and with the purchase of plasma, Boya Bio has signed two procurement contracts with Danxia Bio for a total amount of $1,227 million.
fact, only Boya Bio actually implemented the transaction, the contract amount to Danxia Bio, Danxia Bio did not deliver.
even so, in 2019 Boya Bio signed a pre-purchase contract with Danxia Bio for up to 800 million yuan and paid a deposit of 500 million yuan, the result is still no goods.
after the news broke, Cai Dajian was on top of the wind.
, Gottja is gradually reducing its stake in Boya Bio, and the couple's divorce proceedings are proceeding steadily.
, July 16, 2020, sunflower pharmaceutical founder Guan Yanbin's wife murder case came to an end.
the defendant, Guan Yanbin, was sentenced to 11 years' imprisonment by the Lethu Lu District People's Court in Daqing City for intentional homicide.
defense had previously said Guan had mental illness and surrender, but it was not accepted by the court of first instance.
incident dates back to December 22, 2018, when Guan Yanbin held up a kitchen knife at Zhang Xiaolan's parents' home and slashed his ex-wife four times.
the attack, Guan Yanbin held up a kitchen knife and stabbed himself in the left chest.
rescued in time, the two men were in a state of shock.
10, 2019, Sunflower Pharmaceuticals issued a notice that Guan Yanbin, the company's real controller and former chairman, was arrested on suspicion of intentional homicide.
when the news blew up the internet, Sunflower Pharmaceuticals' share price plummeted.
according to media reports, Guan Yanbin and Zhang Xiaolan's contradictions, the existence of extramarital affairs, illegitim children and the couple's premarital marriage after several children of the company's management rights and other factors.
first instance, Guan Yanbin did not accept the choice of appeal.
December 10, 2020, Guan Yanbin's relatives received the verdict of the second instance: to uphold the judgment of the court of first instance.
, July 9, 2020, ST Kangmei issued a notice that the real controller Ma Xingtian was suspected of illegal disclosure, non-disclosure of important information crime by the public security organs to take coercive measures.
said Ma had been out of any position at the company since May 2020, but was still the ultimate beneficiary.
incident originated on April 30, 2019, the last trading day of the disclosure of the annual report of listed companies, Kangmei Pharmaceuticals issued an annual report.
annual report, Kangmei said it had inflated its monetary capital by 29.944 billion yuan, revenue of 8.898 billion yuan and profit of 3.258 billion yuan.
later investigated by the CSRC, Kangmei Pharmaceuticals inflated its monetary capital by 22.549 billion yuan, 29.944 billion yuan and 36.188 billion yuan, respectively, from 2016 to 2018, with the actual maximum amounting to 36.1 billion yuan.
Comey Pharmaceuticals was exposed as a fraud scandal, because the amount of fraud as high as 90 billion, it is incredible, Comey Pharmaceuticals was eventually fined 600,000, the case involving the relevant personnel were also fined between 100,000 to 900,000, and six of the main responsible persons took 10 years or even life ban on the market.
, June 23, 2020, U.S. health care giant GNC filed for chapter 11 of the U.S. Bankruptcy Code.
and GNC went bankrupt, the biggest losses appear to be China's Ha Pharmaceuticals Group.
june 22nd, Kazakhstan Pharmaceuticals announced that the cumulative book loss on investment in U.S. GNC preferred shares had caused 1.165 billion yuan.
as early as February 2018, ha pharmaceutical group for $299 million (about 2.1 billion yuan) in cash to subscribe for 299.9 million preferred shares issued by GNC.
the conversion of preferred shares into foreign common shares, the group will hold a 40.1 per cent stake in GNC, making it its single largest shareholder.
on September 17th, when a U.S. bankruptcy court judge approved GNC's plan to sell its assets to the largest shareholder and original bidder, Harpoon Group, for $770 million.
day after the meeting, the company clarified urgently that the court's final decision had not yet been officially announced.
matter still needs to be approved at a hearing scheduled for September 22 in the U.S. Supreme Court.
that even if the deal is finalized, there are no plans to bring GNC into the company in the short term.
ha